Anti-leukemic effect of sodium metaarsenite (KML001) in acute myeloid leukemia with breaking-down the resistance of cytosine arabinoside

Yoon,Jin Sun; Kim,Eun Shil; Park,Byeong Bae; Choi,Jung Hye; Won,Young Woong; Kim,Sujong; Lee,Young Yiul

doi:10.3892/ijo.2015.2899

Anti-leukemic effect of sodium metaarsenite (KML001) in acute myeloid leukemia with breaking-down the resistance of cytosine arabinoside

Authors:
- Jin Sun Yoon
- Eun Shil Kim
- Byeong Bae Park
- Jung Hye Choi
- Young Woong Won
- Sujong Kim
- Young Yiul Lee
View Affiliations

Affiliations: Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea, Pharmaceutical Division, Komipharm International Co., Ltd., Seoul, Republic of Korea
Published online on: February 17, 2015 https://doi.org/10.3892/ijo.2015.2899
Pages: 1953-1962

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sodium metaarsenite (NaAs2O3: code name KML001) is an orally bioavailable arsenic compound with potential anti-cancer activity. However, the effect of KML001 has not been studied in acute myeloid leukemia (AML). We investigated the anti-leukemic effect of KML001 in AML, and determined the mode of action of KML001. KML001 inhibited the cellular proliferation in all AML cell lines and primary AML blasts as well as HL-60R (cytosine arabinoside-resistant HL-60) cells, while As2O3 was not effective in primary AML blasts and AML cell lines including HL-60R cells. KML001 induced G1 arrest and apoptosis in HL-60 and HL-60R cells. KML001 inhibited the activation of STAT (signal transducer and activator of transcription) 1, 3, 5, NF-κB, AKT and PI3K, while phosphorylated PTEN was upregulated. In addition, activation of ERK, p38 and JNK was observed in KML001-induced growth inhibition of HL-60 and HL-60R cells. Furthermore, KML001 induced telomeric terminal restriction fragment (TRF) length shortening in a time-dependent manner in HL-60 and HL-60R cells. Real‑time PCR with RNA extracted from KML001-treated HL-60 and HL-60R cells showed a significant reduction of catalytic subunit of telomerase, hTERT, in a time-dependent manner. Additionally, γ-H2AX, a sensitive molecular marker of DNA damage, in HL-60 and HL-60R cells was induced by KML001. These results suggest that KML001 inhibits the proliferation of AML cells including cytosine arabinoside-resistant AML cells via various mechanisms such as cell cycle arrest, induction of apoptosis, inhibition of JAK/STAT and PI3K pathways, activation of MAPK pathway and telomere targeting.

View Figures

View References

1	Waxman S and Anderson KC: History of the development of arsenic derivatives in cancer therapy. Oncologist. 2(Suppl 6): 3–10. 2001. View Article : Google Scholar
2	Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell RP: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 339:1341–1348. 1998. View Article : Google Scholar : PubMed/NCBI
3	Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R and Warrell RP: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 19:3852–3860. 2001.PubMed/NCBI
4	Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res. 6:4957–4964. 2000.
5	Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer. 35:1258–1263. 1999. View Article : Google Scholar
6	Ling YH, Jiang JD, Holland JF and Perez-Soler R: Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol. 62:529–538. 2002. View Article : Google Scholar : PubMed/NCBI
7	Miller WH, Schipper HM, Lee JS, Singer J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res. 62:3893–3903. 2002.PubMed/NCBI
8	Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY and Chen Z: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia: As₂O₃ induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 88:1052–1061. 1996.PubMed/NCBI
9	Hug N and Lingner J: Telomere length homeostasis. Chromosoma. 115:413–425. 2006. View Article : Google Scholar : PubMed/NCBI
10	Chou WC, Hawkins AL, Barrett JF, Griffin CA and Dang CV: Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest. 108:1541–1547. 2001. View Article : Google Scholar : PubMed/NCBI
11	Litzow MR: Arsenic trioxide. Expert Opin Pharmacother. 9:1773–1785. 2008. View Article : Google Scholar : PubMed/NCBI
12	Phatak P, Dai F, Butler M, Nandakumar MP, Gutierrez PL, Edelman MJ, Hendriks H and Burger AM: KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Clin Cancer Res. 14:4593–4602. 2008. View Article : Google Scholar : PubMed/NCBI
13	Glienke W, Chow KU, Bauer N and Bergmann L: Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma. 47:1629–1638. 2006. View Article : Google Scholar : PubMed/NCBI
14	Jin JO, Song MG, Kim YN, Park JI and Kwak JY: The mechanism of fucoidan-induced apoptosis in leukemic cells: involvement of ERK1/2, JNK, glutathione, and nitric oxide. Mol Carcinog. 49:771–782. 2010.PubMed/NCBI
15	Yoon JS, Won YW, Kim SJ, Oh SJ, Kim ES, Kim BK, Cho CG, Choi JH, Park BB, Lee MH and Lee YY: Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways. Invest New Drugs. 30:2284–2293. 2012. View Article : Google Scholar : PubMed/NCBI
16	Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51. 1995. View Article : Google Scholar : PubMed/NCBI
17	d’Adda di Fagagna F, Hande MP, Tong WM, Roth D, Lansdorp PM, Wang ZQ and Jackson SP: Effects of DNA nonhomologous end-joining factors on telomere length and chromosomal stability in mammalian cells. Curr Biol. 11:1192–1196. 2001. View Article : Google Scholar
18	Cawthon RM: Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 37:e212009. View Article : Google Scholar : PubMed/NCBI
19	Blackburn EH: Telomere states and cell fates. Nature. 408:53–56. 2000. View Article : Google Scholar : PubMed/NCBI
20	d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP and Jackson SP: A DNA damage checkpoint response in telomere-initiated senescence. Nature. 426:194–198. 2003. View Article : Google Scholar
21	Phatak P, Cookson JC, Dai F, Smith V, Gartenhaus RB, Stevens MF and Burger AM: Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer. 96:1223–1233. 2007. View Article : Google Scholar : PubMed/NCBI
22	Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
23	Dynlacht BD: Regulation of transcription by proteins that control the cell cycle. Nature. 389:149–152. 1997. View Article : Google Scholar : PubMed/NCBI
24	Darnell JE, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
25	Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
26	Akira S: Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells. 17:138–146. 1999. View Article : Google Scholar : PubMed/NCBI
27	Hirano T, Ishihara K and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 19:2548–2556. 2000. View Article : Google Scholar : PubMed/NCBI
28	Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H and Wilson MB: Control of myeloid differentiation and survival by Stats. Oncogene. 19:2612–2618. 2000. View Article : Google Scholar : PubMed/NCBI
29	Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M and Lord JM: Serine/threonine protein kinases and apoptosis. Exp Cell Res. 256:34–41. 2000. View Article : Google Scholar : PubMed/NCBI
30	Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 23:2838–2849. 2004. View Article : Google Scholar : PubMed/NCBI
31	Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep. 14:129–138. 2012. View Article : Google Scholar : PubMed/NCBI
32	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
33	Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 19:6680–6686. 2000. View Article : Google Scholar
34	Ortega-Molina A and Serrano M: PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab. 24:184–189. 2013. View Article : Google Scholar
35	Sawyers CL: Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev. 12:111–115. 2002. View Article : Google Scholar : PubMed/NCBI
36	Janus A, Linke A, Cebula B, Robak T and Smolewski P: Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine. Anticancer Drugs. 20:693–701. 2009. View Article : Google Scholar : PubMed/NCBI
37	Baldwin AS: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI
38	Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin AS: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 19:5785–5799. 1999.PubMed/NCBI
39	Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C and Strauss M: NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 19:2690–2698. 1999.PubMed/NCBI
40	Zhang Y, Cao EH and Qin JF: Up-regulation of telomere-binding TRF1, TRF2 related to reactive oxygen species induced by As₂O₃ in MGC-803 cells. Eur J Pharmacol. 516:1–9. 2005. View Article : Google Scholar : PubMed/NCBI